Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06452160 · ClinicalTrials.gov registry record · Phase 1
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
A Phase 1 study of Solid Tumor and Mesothelioma, sponsored by BridGene Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
- 1
- Study location
NCT06452160 is a Phase 1 study of Solid Tumor and Mesothelioma that is actively recruiting participants, run by BridGene Biosciences. The registered enrollment target is 103 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06452160, a Phase 1 study of Solid Tumor and Mesothelioma, is actively recruiting participants, sponsored by BridGene Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in solid tumor patients.
Conditions Studied
Interventions
- DRUG BGC515
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2024-06-27 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06452160
The ClinicalTrials.gov registry entry for NCT06452160 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (53% lower). The listed sponsor is BridGene Biosciences, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which BGC515 is the first listed.
NCT06452160 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06452160 about?
NCT06452160 is a clinical study titled "A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors". The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in solid tumor patients.
What is the current status of trial NCT06452160?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2024-06-27. Estimated completion is 2027-12.
What conditions does trial NCT06452160 study?
This clinical trial studies the following conditions: Solid Tumor, Mesothelioma, Epithelioid Hemangioendothelioma(EHE).
What interventions are being tested in trial NCT06452160?
The interventions under investigation include: BGC515 (DRUG).
Who is sponsoring clinical trial NCT06452160?
This trial is sponsored by BridGene Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06452160 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.